The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury

Letter of support for drug-induced liver injury (DILI) biomarker

The objectives of DILI WP3 were to qualify one or a set of new biomarkers with respect to: an early or earlier diagnosis of DILI as compared to current diagnostic rules the ability to predict DILI outcome, with particular emphasis on severe DILI/acute liver failure the prognosis and monitoring of progression and regression of DILI the differentiation between patients who incur true drug-induced...

The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis. Preface.

Drug-Induced Liver Injury

1Office of Computational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA 2Center of Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany 3Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA 4Division of Bioinformatics and Biostatistics, National Center for Toxicological Research,...

Drug-induced liver injury.

Drug-induced liver injury is a frequent cause of hepatic dysfunction. Reliably establishing whether the liver disease was caused by a drug requires the exclusion of other plausible causes and the search for a clinical drug signature. The drug signature consists of the pattern of liver test abnormality, the duration of latency to symptomatic presentation, the presence or absence of immune-mediat...

Drug-induced Liver Injury.

Drug-induced liver injury (DILI) is common and nearly all classes of medications can cause liver disease. Most cases of DILI are benign, and improve after drug withdrawal. It is important to recognize and remove the offending agent as quickly as possible to prevent the progression to chronic liver disease and/or acute liver failure. There are no definite risk factors for DILI, but pre-existing ...